Cron M, Zemirline C, Beranger J, Privat V
Sogeval Laboratories, Pet Business Unit, BP 2227, 200 avenue de Mayenne, Laval Cedex 9 53061, France.
Sogeval Laboratories, Research and Development Department, Parc Technopole, BP 96105, Avenue Pierre de Coubertin, Laval Cedex 9 53061, France.
Vet Rec. 2014 Jul 26;175(4):88. doi: 10.1136/vr.101438. Epub 2014 May 14.
At a time when antimicrobial resistance is a global concern in human and animal health, it is of primary importance to draw attention to the problem of compliance with antibiotic therapy in animals hard to medicate such as cats. Resistance may develop because of poor patient compliance with the prescribed course of antibiotic therapy. Increasing palatability might enhance administration compliance. We assessed the acceptability of EFEX tablets, a new oral marbofloxacin formulation for cats. The objective of this study was to compare EFEX to two commercial formulations of marbofloxacin: MARBOCYL P palatable tablets and MARBOCYL Vet tablets. Acceptance tests were run in experimental conditions in 24 cats to compare the spontaneous intake and full consumption of the three pharmaceutical products. The results indicated that EFEX was more palatable than MARBOCYL Vet (0.001<P <0.01) and equally comparable with MARBOCYL P in palatability. There was no difference in the short-term adverse effects between the products.
在抗菌药物耐药性成为人类和动物健康领域全球关注问题的当下，关注诸如猫这类难以给药的动物的抗生素治疗依从性问题至关重要。由于患者对抗生素规定疗程的依从性差，可能会产生耐药性。提高适口性或许能增强给药依从性。我们评估了EFEX片剂（一种新的猫用口服马波沙星制剂）的可接受性。本研究的目的是将EFEX与两种马波沙星商业制剂进行比较：MARBOCYL P适口性片剂和MARBOCYL Vet片剂。在实验条件下对24只猫进行了接受性测试，以比较这三种药品的自发摄入量和完全消耗量。结果表明，EFEX比MARBOCYL Vet更适口（0.001<P <0.01），在适口性方面与MARBOCYL P相当。产品之间的短期不良反应没有差异。
